Caso, Francesco http://orcid.org/0000-0002-8928-2520
Navarini, Luca http://orcid.org/0000-0001-8537-1510
Carubbi, Francesco http://orcid.org/0000-0003-1958-5136
Picchianti-Diamanti, Andrea http://orcid.org/0000-0002-8552-4641
Chimenti, Maria Sole http://orcid.org/0000-0002-1343-1729
Tasso, Marco
Currado, Damiano
Ruscitti, Piero http://orcid.org/0000-0003-3487-8551
Ciccozzi, Massimo http://orcid.org/0000-0003-3866-9239
Annarumma, Antonio
Laganà, Bruno http://orcid.org/0000-0002-7660-8974
Perricone, Roberto http://orcid.org/0000-0002-2368-9766
Afeltra, Antonella http://orcid.org/0000-0003-2440-1995
Giacomelli, Roberto http://orcid.org/0000-0003-0670-9638
Scarpa, Raffaele http://orcid.org/0000-0002-5808-6607
Costa, Luisa http://orcid.org/0000-0001-7022-9685
Article History
Received: 29 July 2019
Accepted: 27 September 2019
First Online: 11 October 2019
Compliance with ethical standards
:
: The authors declare that they have no conflicts of interest in this work. Francesco Caso: conflict of interest and relationships with pharma agencies—none; Luca Navarini: conflict of interest and relationships with pharma agencies—none; Francesco Carubbi: conflict of interest and relationships with pharma agencies—none; Andrea Picchianti-Diamanti: conflict of interest and relationships with pharma agencies—none; Maria Sole Chimenti: conflict of interest and relationships with pharma agencies—none; Marco Tasso: conflict of interest and relationships with pharma agencies—none; Damiano Currado: conflict of interest and relationships with pharma agencies—none; Piero Ruscitti: conflict of interest and relationships with pharma agencies—PR received speaker honoraria and/or grants from BMS, MSD, Ely Lilly, SOBI and Pfizer outside this work; Massimo Ciccozzi: conflict of interest and relationships with pharma agencies—none; Antonio Annarumma: conflict of interest and relationships with pharma agencies—none; Bruno Laganà: conflict of interest and relationships with pharma agencies—none; Roberto Perricone: conflict of interest and relationships with pharma agencies—none; Antonella Afeltra: conflict of interest and relationships with pharma agencies—none; Roberto Giacomelli: conflict of interest and relationships with pharma agencies—RG received speaker honoraria and/or grants from Abbvie, Roche, Actelion, BMS, MSD, Ely Lilly, SOBI and Pfizer outside this work; Raffaele Scarpa: conflict of interest and relationships with pharma agencies—RS received speaker honoraria and/or grants from Abbvie, Celgene, MSD, Ely Lilly, Novartis, and Pfizer; Luisa Costa: conflict of interest and relationships with pharma agencies—none.